The Chinese Solar Machine Layer by Layer Fire in the Library The Mystery Behind Anesthesia
In the last decade, antibody-based drugs have provided treatments for allergies, infectious diseases, cancers, and autoimmune diseases such as rheumatoid arthritis. But antibodies are large molecules, expensive to manufacture and tricky to maintain, requiring refrigerated storage. And extensive patent protections tie the hands of drug companies that want to expand their use.
Now researchers at biotech startup Avidia, in Mountain View, CA, have engineered a new class of proteins they call "avimers," which the company says are easier to make and store -- and require fewer lawyers to bring to market. Avidia scientists have shown that an avimer designed to inhibit human interleukin-6 (IL-6) -- a protein implicated in rheumatoid arthritis and Crohn's disease -- works in mice. Avidia plans to move the avimer into human trials later this year.
To read the entire article you must log in:
Most of our content — all daily news, blogs, and videos — is free. Magazine stories are paid. To read this story, you must have a subscription or you must use a reading credit. Registration to Technology Review is free and entitles registrants to three free reading credits.
Manufacturing in the United States is in trouble. That's bad news not just for the country's economy but for the future of innovation.